Trial · NCT00256997
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced a Clinical Exacerbation From Month 3 Post-Randomization | Risperidone Long-Acting Injection (LAI) | 48.1 | Percentage of participants | ||
| Percentage of Participants Who Experienced a Clinical Exacerbation From Month 3 Post-Randomization | Oral Atypical Antipsychotic | 43.0 | Percentage of participants | ||
| Percentage of Participants Who Experienced a Clinical Exacerbation | Risperidone Long-acting Injection (LAI) | 54.4 | Percentage of participants | ||
| Percentage of Participants Who Experienced a Clinical Exacerbation | Oral Atypical Antipsychotic | 54.7 | Percentage of participants | ||
| Time to First Clinical Exacerbation | Risperidone Long-acting Injection (LAI) | 10.4 | Standard Error 0.80 | Months | |
| Time to First Clinical Exacerbation | Oral Atypical Antipsychotic | 11.2 | Standard Error 0.93 | Months | |
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Month 24 | Risperidone Long-acting Injection (LAI) | Baseline (n=79, 85) | 77.6 | Standard Deviation 17.24 | Units on a scale |
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Month 24 | Oral Atypical Antipsychotic | Baseline (n=79, 85) | 76.5 | Standard Deviation 17.83 | Units on a scale |
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Month 24 | Risperidone Long-acting Injection (LAI) | Change at Month 24: Total score (n=67, 67) | -9.6 | Standard Deviation 19.80 | Units on a scale |
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Month 24 | Oral Atypical Antipsychotic | Change at Month 24: Total score (n=67, 67) | -12.4 | Standard Deviation 21.83 | Units on a scale |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Risperidone Long-acting Injection (LAI) | Baseline: Mild or better (n=79, 85) | 18 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Oral Atypical Antipsychotic | Baseline: Mild or better (n=79, 85) | 26 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Risperidone Long-acting Injection (LAI) | Baseline: Moderate, marked and severe (n=79, 85) | 61 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Oral Atypical Antipsychotic | Baseline: Moderate, marked and severe (n=79, 85) | 59 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Risperidone Long-acting Injection (LAI) | Month 24/EW: Mild or better (n=67, 68) | 36 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Oral Atypical Antipsychotic | Month 24/EW: Mild or better (n=67, 68) | 39 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Risperidone Long-acting Injection (LAI) | Month 24/EW:Moderate,marked and severe (n=67, 68) | 31 | participants | |
| Number of Participants With Clinical Global Impression of Severity (CGI-S) | Oral Atypical Antipsychotic | Month 24/EW:Moderate,marked and severe (n=67, 68) | 29 | participants | |
| Number of Participants With Clinical Global Impression of Change (CGI-C) | Risperidone Long-acting Injection (LAI) | Month 24/EW:At least minimally improved(n= 67,68) | 48 | Participants | |
| Number of Participants With Clinical Global Impression of Change (CGI-C) | Oral Atypical Antipsychotic | Month 24/EW:At least minimally improved(n= 67,68) | 38 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00256997/results